Studies of influenza vaccine to achieve new breakthroughs

ZHOU Dong-ming Shanghai Pasteur Institute research group has made breakthroughs in the field of influenza vaccine research, related research recently published online in "gene therapy", which studies have shown that targeting conserved influenza miRNA fragments can be used as a new means of prevention and control of influenza .

Influenza viruses can infect including human, avian and other hosts. According to statistics, every year about 3 million to 5 million patients with severe influenza, which killed up to 500,000. Flu viruses spread rapidly, widespread, virulent, pose a serious threat to human health, is one of the world's most serious public health problems. Because the influenza virus mutates rapidly, developing new, efficient, universal flu vaccine flu become a hot research field.

Under the guidance of ZHOU Dong-ming, Shanghai Pasteur Institute anti-infection immunity and vaccine research group Zhang Hongbo postdoctoral, doctoral Tang Xin Ying et al., Screened 7 against influenza NP conserved genes and cells through software design, Recombinant mouse Beta-defensin 14 http://www.cusabio.com/Recombinant-Protein/Recombinant-mouse-Beta-defensin-14-11030925.html and has Efficient antagonistic miRNA, miRNA cloning they screened to replication-defective AdC68 E1 region expression, access to seven different influenza-specific miRNA expression of adenovirus.

Researchers in 1011vp AdC68-amiRNA immunized mice against homologous H1N1 influenza infection have 100% protective effect, for heterologous H5N1 and H9N2 as well as some protective effect (40% to 100%).